CAMBRIDGE, Mass., Dec. 07, 2017 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray, Ph.D., chief executive officer and president of Jounce, will present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference at 4:30 p.m. ET on Thursday, December 14, 2017 in New York.
A live webcast of the presentation will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.
Investor Contact:
Komal Joshi
Jounce Therapeutics, Inc.
(857) 320-2523
[email protected]
Media Contact:
Katie Engleman
Pure Communications, Inc.
(910) 509-3977
[email protected]


Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



